Celcuity Inc. (NASDAQ:CELC) Receives $28.67 Consensus Target Price from Brokerages

Celcuity Inc. (NASDAQ:CELC) has earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $29.17.

Several equities analysts have commented on CELC shares. Lifesci Capital started coverage on Celcuity in a report on Monday, August 26th. They set an “outperform” rating and a $27.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Celcuity in a report on Thursday, August 15th. Stifel Nicolaus raised their price objective on shares of Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Celcuity in a research note on Thursday, August 15th. Finally, Leerink Partners started coverage on Celcuity in a report on Monday, July 22nd. They set an “outperform” rating and a $29.00 price objective for the company.

Institutional Trading of Celcuity

Institutional investors and hedge funds have recently modified their holdings of the business. Commodore Capital LP increased its holdings in Celcuity by 3.6% in the fourth quarter. Commodore Capital LP now owns 1,754,704 shares of the company’s stock worth $25,566,000 after purchasing an additional 60,563 shares in the last quarter. Baker BROS. Advisors LP increased its holdings in shares of Celcuity by 189.9% during the first quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company’s stock valued at $33,534,000 after acquiring an additional 1,017,000 shares in the last quarter. Perceptive Advisors LLC bought a new stake in shares of Celcuity during the fourth quarter valued at approximately $21,583,000. Samlyn Capital LLC boosted its position in shares of Celcuity by 92.4% during the second quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock valued at $21,735,000 after buying an additional 637,190 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Celcuity by 1.0% in the first quarter. Vanguard Group Inc. now owns 828,597 shares of the company’s stock worth $17,898,000 after purchasing an additional 7,821 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors.

Celcuity Trading Down 0.1 %

Shares of CELC stock opened at $15.26 on Friday. Celcuity has a 12 month low of $8.39 and a 12 month high of $22.19. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.54. The business’s 50 day moving average is $15.78 and its two-hundred day moving average is $16.61. The company has a market cap of $535.64 million, a PE ratio of -5.49 and a beta of 0.75.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. During the same period last year, the company posted ($0.66) EPS. Equities analysts predict that Celcuity will post -2.54 EPS for the current year.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.